Literature DB >> 28635973

Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.

Shirley M Bluethmann1, Caitlin C Murphy2, Jasmin A Tiro2, Michelle A Mollica3, Sally W Vernon4, Leona Kay Bartholomew4.   

Abstract

PURPOSE/
OBJECTIVES: Adjuvant endocrine therapy (AET) has been shown to improve survival in hormone receptor-positive breast cancer survivors, but as many as half do not complete recommended treatment. Management of medication-related side effects and engagement with providers are two potentially modifiable factors, but their associations with adherence are not well understood. The aims were to build on survey results to qualitatively explore survivors' experiences with prescribed AET to (a) describe appraisal and management of AET side effects and (b) deconstruct decisions to initiate, discontinue, or maintain AET.
. RESEARCH APPROACH: The authors used a mixed-methods explanatory sequence research design with a qualitative emphasis.
.
SETTING: Survivors were recruited from a clinical cancer registry maintained at the University of Texas Southwestern Medical Center, which includes the Harold C. Simmons Comprehensive Cancer Center (National Cancer Institute-designated), in Dallas.
. PARTICIPANTS: 452 survivors completed a survey, and 30 took part in telephone interviews.
. METHODOLOGIC APPROACH: Qualitative methods were used in which the authors recorded and transcribed interviews for analysis and used open coding to reduce data into themes.
.
FINDINGS: Among adherent survivors, the themes of tolerance of side effects and perseverance were strong. Nonadherent survivors expressed more difficulty managing side effects and perceived fewer benefits when side effects were bothersome. The most common side effects mentioned by all survivors were menopausal symptoms and joint pain; less common side effects were cognitive decline and cardiac distress. Some sought advice from their oncology team. Nonadherent survivors appeared initially motivated to maintain AET but identified a tolerance limit for side effects after which a provider's recommendation was less influential in their decision to maintain or discontinue AET.
.
INTERPRETATION: This study elucidated adherence as a complex continuum of behaviors, appraisals, and decision points. These insights may be particularly useful in counseling survivors taking AET and promoting timely delivery of clinical interventions to enhance adherence.
. IMPLICATIONS FOR NURSING: Nurses should be involved in the planning and implementation of clinical interventions to manage side effects and other barriers to AET adherence.

Entities:  

Keywords:  adjuvant endocrine therapy; breast cancer survivors; side effects; survivorship care; symptoms


Mesh:

Substances:

Year:  2017        PMID: 28635973      PMCID: PMC5507080          DOI: 10.1188/17.ONF.E101-E110

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  35 in total

1.  Mixed methods in health psychology: theoretical and practical considerations of the third paradigm.

Authors:  E Dures; N Rumsey; M Morris; K Gleeson
Journal:  J Health Psychol       Date:  2010-10-26

2.  Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.

Authors:  Jennifer R Garreau; Tammy Delamelena; Deb Walts; Kasra Karamlou; Nathalie Johnson
Journal:  Am J Surg       Date:  2006-10       Impact factor: 2.565

3.  Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention.

Authors:  Jennifer H Lin; Shumin M Zhang; JoAnn E Manson
Journal:  Cancer Prev Res (Phila)       Date:  2011-09

Review 4.  Behavioral Interventions to Enhance Adherence to Hormone Therapy in Breast Cancer Survivors: A Systematic Literature Review.

Authors:  Alejandra Hurtado-de-Mendoza; Mark L Cabling; Tania Lobo; Chiranjeev Dash; Vanessa B Sheppard
Journal:  Clin Breast Cancer       Date:  2016-03-31       Impact factor: 3.225

Review 5.  Adherence to endocrine therapy in breast cancer adjuvant and prevention settings.

Authors:  Rowan T Chlebowski; Jisang Kim; Reina Haque
Journal:  Cancer Prev Res (Phila)       Date:  2014-01-17

Review 6.  Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy.

Authors:  David Cella; Lesley J Fallowfield
Journal:  Breast Cancer Res Treat       Date:  2007-09-18       Impact factor: 4.872

7.  Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis.

Authors:  Duveken B Y Fontein; Caroline Seynaeve; Peyman Hadji; Elysée T M Hille; Willemien van de Water; Hein Putter; Elma Meershoek-Klein Kranenbarg; Annette Hasenburg; Robert J Paridaens; Jean-Michel Vannetzel; Christos Markopoulos; Yasuo Hozumi; John M S Bartlett; Stephen E Jones; Daniel William Rea; Johan W R Nortier; Cornelis J H van de Velde
Journal:  J Clin Oncol       Date:  2013-04-22       Impact factor: 44.544

8.  Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients.

Authors:  Kimberly R Jacob Arriola; Tamara A Mason; Kari Ann Bannon; Carol Holmes; Cecil Lamonte Powell; Kandra Horne; Ruth O'Regan
Journal:  Patient Educ Couns       Date:  2014-01-10

9.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

Authors:  C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto
Journal:  Lancet       Date:  2011-07-28       Impact factor: 79.321

10.  Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.

Authors:  Mitch Dowsett; Jack Cuzick; Jim Ingle; Alan Coates; John Forbes; Judith Bliss; Marc Buyse; Michael Baum; Aman Buzdar; Marco Colleoni; Charles Coombes; Claire Snowdon; Michael Gnant; Raimund Jakesz; Manfred Kaufmann; Francesco Boccardo; Jon Godwin; Christina Davies; Richard Peto
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

View more
  15 in total

1.  Patient, provider, and nurse preferences of patient reported outcomes (PRO) and side effect management during cancer treatment of underrepresented racial and ethnic minority groups, rural and economically disadvantaged patients: a mixed methods study.

Authors:  Bernard Tawfik; Ellen Burgess; Mikaela Kosich; Shoshana Adler Jaffe; Dolores D Guest; Ursa Brown-Glaberman; V Shane Pankratz; Andrew Sussman
Journal:  Cancer Causes Control       Date:  2022-07-13       Impact factor: 2.532

Review 2.  Effects of Endocrine Therapy on Cognitive Function in Patients with Breast Cancer: A Comprehensive Review.

Authors:  Lucy R Haggstrom; Janette L Vardy; Emma-Kate Carson; Davendra Segara; Elgene Lim; Belinda E Kiely
Journal:  Cancers (Basel)       Date:  2022-02-12       Impact factor: 6.639

3.  Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance).

Authors:  Shirley M Bluethmann; Catherine M Alfano; Jonathan D Clapp; George Luta; Brent J Small; Arti Hurria; Harvey J Cohen; Steven Sugarman; Hyman B Muss; Claudine Isaacs; Jeanne S Mandelblatt
Journal:  Breast Cancer Res Treat       Date:  2017-06-26       Impact factor: 4.872

4.  Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016.

Authors:  Erin J Aiello Bowles; Cody Ramin; Diana S M Buist; Heather Spencer Feigelson; Sheila Weinmann; Lene H S Veiga; Clara Bodelon; Rochelle E Curtis; Jacqueline B Vo; Amy Berrington de Gonzalez; Gretchen L Gierach
Journal:  Breast Cancer Res Treat       Date:  2022-03-11       Impact factor: 4.872

Review 5.  Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer.

Authors:  Katherine E Reeder-Hayes; Melissa A Troester; Stephanie B Wheeler
Journal:  Oncologist       Date:  2021-09-28

6.  The impact of health symptoms on health-related quality of life in early-stage breast cancer survivors.

Authors:  K M de Ligt; M Heins; J Verloop; N P M Ezendam; C H Smorenburg; J C Korevaar; S Siesling
Journal:  Breast Cancer Res Treat       Date:  2019-09-11       Impact factor: 4.872

7.  Both "Vitamin L for Life" and "One Milligram of Satan": A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer.

Authors:  Kirsti I Toivonen; Devesh Oberoi; Kathryn King-Shier; Katherine-Ann L Piedalue; Joshua A Rash; Linda E Carlson; Tavis S Campbell
Journal:  Curr Oncol       Date:  2021-07-05       Impact factor: 3.677

8.  Study design and methods for the using exercise to relieve joint pain and improve AI adherence in older breast cancer survivors (REJOIN) trial.

Authors:  Shirley M Bluethmann; Cristina Truica; Heidi D Klepin; Nancy Olsen; Christopher Sciamanna; Vernon M Chinchilli; Kathryn H Schmitz
Journal:  J Geriatr Oncol       Date:  2021-05-26       Impact factor: 3.929

9.  Women's coping strategies during the first three months of adjuvant endocrine therapy for breast cancer.

Authors:  Susanne Ahlstedt Karlsson; Catarina Wallengren; Roger Olofsson Bagge; Ingela Henoch
Journal:  Nurs Open       Date:  2019-12-13

10.  How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support.

Authors:  Maurice J Berkowitz; Carlie K Thompson; Laura T Zibecchi; Minna K Lee; Elani Streja; Jacob S Berkowitz; Cachet M Wenziger; Jennifer L Baker; Maggie L DiNome; Deanna J Attai
Journal:  J Cancer Surviv       Date:  2020-08-17       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.